Antithrombin III human

DB11598

biotech approved

Deskripsi

A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 2.5 - 3.8 hs
Volume Distribusi Distributed into plasma (39%), extravascular space (49%), and vascular endothelial cells (11%).
Klirens (Clearance) -

Absorpsi

Therapeutic target plasma concentrations in patients with congenital antithrombin III deficiency range from 80–120% of values in healthy adults. At plasma concentrations ?70% of normal, increased thrombin generation. Supraphysiologic plasma concentrations (e.g., 150–200% of normal) have increased bleeding risk in patients with sepsis and disseminated intravascular coagulation, not known whether supraphysiologic concentrations increase bleeding risk in patients with congenital antithrombin III deficiency.

Metabolisme

<5% metabolized to low molecular weight breakdown products.

Rute Eliminasi

Complexes of antithrombin III with thrombin or other proteinases cleared principally by liver and excreted in urine.

Interaksi Makanan

1 Data
  • 1. Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Interaksi Obat

1130 Data
Apixaban Apixaban may increase the anticoagulant activities of Antithrombin III human.
Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Antithrombin III human.
Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Antithrombin III human.
Deferasirox The risk or severity of gastrointestinal bleeding can be increased when Antithrombin III human is combined with Deferasirox.
Ursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Glycochenodeoxycholic Acid.
Cholic Acid The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Cholic Acid.
Glycocholic acid The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Glycocholic acid.
Deoxycholic acid The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Deoxycholic acid.
Taurocholic acid The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Taurocholic acid.
Obeticholic acid The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Obeticholic acid.
Chenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Tauroursodeoxycholic acid.
Bamet-UD2 The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Bamet-UD2.
Dehydrocholic acid The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Dehydrocholic acid.
Hyodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Hyodeoxycholic Acid.
Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Antithrombin III human.
Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Antithrombin III human.
Obinutuzumab The risk or severity of bleeding and hemorrhage can be increased when Antithrombin III human is combined with Obinutuzumab.
Rivaroxaban Antithrombin III human may increase the anticoagulant activities of Rivaroxaban.
Sugammadex The risk or severity of bleeding and hemorrhage can be increased when Antithrombin III human is combined with Sugammadex.
Tibolone Tibolone may increase the anticoagulant activities of Antithrombin III human.
Tipranavir The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Antithrombin III human.
Urokinase Urokinase may increase the anticoagulant activities of Antithrombin III human.
Vitamin E Vitamin E may increase the anticoagulant activities of Antithrombin III human.
Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Antithrombin III human.
Ginkgo biloba Ginkgo biloba may increase the anticoagulant activities of Antithrombin III human.
Ifosfamide The risk or severity of bleeding can be increased when Ifosfamide is combined with Antithrombin III human.
Quinine The therapeutic efficacy of Antithrombin III human can be increased when used in combination with Quinine.
Quinidine The therapeutic efficacy of Antithrombin III human can be increased when used in combination with Quinidine.
Tamoxifen The risk or severity of bleeding can be increased when Tamoxifen is combined with Antithrombin III human.
Toremifene The risk or severity of bleeding can be increased when Toremifene is combined with Antithrombin III human.
Pentoxifylline The therapeutic efficacy of Antithrombin III human can be increased when used in combination with Pentoxifylline.
Pentosan polysulfate Pentosan polysulfate may increase the anticoagulant activities of Antithrombin III human.
Levocarnitine The therapeutic efficacy of Antithrombin III human can be increased when used in combination with Levocarnitine.
Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Antithrombin III human.
Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Antithrombin III human.
Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Antithrombin III human.
Mestranol The risk or severity of adverse effects can be increased when Mestranol is combined with Antithrombin III human.
Estrone sulfate Estrone sulfate may decrease the anticoagulant activities of Antithrombin III human.
Quinestrol Quinestrol may decrease the anticoagulant activities of Antithrombin III human.
Hexestrol Hexestrol may decrease the anticoagulant activities of Antithrombin III human.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Antithrombin III human.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Antithrombin III human.
Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Antithrombin III human.
Esterified estrogens Esterified estrogens may decrease the anticoagulant activities of Antithrombin III human.
Zeranol Zeranol may decrease the anticoagulant activities of Antithrombin III human.
Equol Equol may decrease the anticoagulant activities of Antithrombin III human.
Methallenestril Methallenestril may decrease the anticoagulant activities of Antithrombin III human.
Epimestrol Epimestrol may decrease the anticoagulant activities of Antithrombin III human.
Moxestrol Moxestrol may decrease the anticoagulant activities of Antithrombin III human.
Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Antithrombin III human.
Estradiol benzoate Estradiol benzoate may decrease the anticoagulant activities of Antithrombin III human.
Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Antithrombin III human.
Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Antithrombin III human.
Biochanin A Biochanin A may decrease the anticoagulant activities of Antithrombin III human.
Formononetin Formononetin may decrease the anticoagulant activities of Antithrombin III human.
Estriol Estriol may decrease the anticoagulant activities of Antithrombin III human.
Limaprost The risk or severity of adverse effects can be increased when Limaprost is combined with Antithrombin III human.
Icosapent The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Antithrombin III human.
Mesalazine The risk or severity of bleeding can be increased when Mesalazine is combined with Antithrombin III human.
Indomethacin The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Antithrombin III human.
Nabumetone The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Antithrombin III human.
Ketorolac The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Antithrombin III human.
Tenoxicam The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Antithrombin III human.
Celecoxib The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Antithrombin III human.
Tolmetin The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Antithrombin III human.
Rofecoxib The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Antithrombin III human.
Piroxicam The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Antithrombin III human.
Fenoprofen The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Antithrombin III human.
Valdecoxib The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Antithrombin III human.
Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Antithrombin III human.
Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Antithrombin III human.
Flurbiprofen The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Antithrombin III human.
Etodolac The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Antithrombin III human.
Mefenamic acid The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Antithrombin III human.
Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Antithrombin III human.
Sulfasalazine The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Antithrombin III human.
Phenylbutazone The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Antithrombin III human.
Meloxicam The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Antithrombin III human.
Carprofen The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Antithrombin III human.
Diflunisal The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Antithrombin III human.
Salicylic acid The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Antithrombin III human.
Meclofenamic acid The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Antithrombin III human.
Oxaprozin The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Antithrombin III human.
Ketoprofen The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Antithrombin III human.
Balsalazide The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Antithrombin III human.
Olsalazine The risk or severity of bleeding can be increased when Olsalazine is combined with Antithrombin III human.
Lumiracoxib The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Antithrombin III human.
Magnesium salicylate The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Antithrombin III human.
Salsalate The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Antithrombin III human.
Choline magnesium trisalicylate The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Antithrombin III human.
Antrafenine The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Antithrombin III human.
Aminophenazone The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Antithrombin III human.
Antipyrine The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Antithrombin III human.
Tiaprofenic acid The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Antithrombin III human.
Etoricoxib The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Antithrombin III human.
Taxifolin The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Antithrombin III human.
Oxyphenbutazone The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Antithrombin III human.

Target Protein

Antithrombin-III SERPINC1

Referensi & Sumber

Artikel (PubMed)
  • PMID: 8871458
    Cavenagh JD, Colvin BT: Guidelines for the management of thrombophilia. Department of Haematology, The Royal London Hospital, Whitechapel, London, UK. Postgrad Med J. 1996 Feb;72(844):87-94.
  • PMID: 1502714
    Menache D, Grossman BJ, Jackson CM: Antithrombin III: physiology, deficiency, and replacement therapy. Transfusion. 1992 Jul-Aug;32(6):580-8.
  • PMID: 17515857
    Aibiki M, Fukuoka N, Nishiyama T, Maekawa S, Shirakawa Y: Differences in antithrombin III activities by administration method in critical patients with disseminated intravascular coagulation: a pharmacokinetic study. Shock. 2007 Aug;28(2):141-7.
  • PMID: 65284
    Collen D, Schetz J, de Cock F, Holmer E, Verstraete M: Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration. Eur J Clin Invest. 1977 Feb;7(1):27-35.
Link

Contoh Produk & Brand

Produk: 11 • International brands: 1
Produk
  • Antithrombin III Immuno
    Powder, for solution • - • Intravenous • Canada • Approved
  • Antithrombin III Nf
    Kit; Powder, for solution • 550 unit / vial • Intravenous • Canada • Approved
  • Antithrombin III Nf
    Kit; Powder, for solution • 1100 unit / vial • Intravenous • Canada • Approved
  • Thrombate III
    Injection, powder, lyophilized, for solution; Kit • 50 [iU]/1mL • Intravenous • US • Approved
  • Thrombate III
    Injection, powder, lyophilized, for solution; Kit • 50 [iU]/1mL • Intravenous • US • Approved
  • Thrombate III
    Injection, powder, lyophilized, for solution; Kit • 50 [iU]/1mL • Intravenous • US • Approved
  • Thrombate III
    Powder, for solution • 500 unit / vial • Intravenous • Canada • Approved
  • Thrombate III
    Powder, for solution • 1000 unit / vial • Intravenous • Canada • Approved
Menampilkan 8 dari 11 produk.
International Brands
  • Thrombotrol-VF — CSL Behring

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul